<DOC>
	<DOCNO>NCT00425750</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth tumor cell block enzymes need cell growth . It may also stop growth tumor cell block blood flow tumor . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving bortezomib together docetaxel may kill tumor cell . PURPOSE : This phase II trial study well give bortezomib together docetaxel work treat patient recurrent metastatic head neck cancer .</brief_summary>
	<brief_title>Bortezomib Docetaxel Treating Patients With Recurrent Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall response rate patient recurrent and/or metastatic squamous cell carcinoma head neck treat bortezomib docetaxel . Secondary - Determine time progression patient treat regimen . - Determine toxicity regimen . - Determine duration response patient treat regimen . - Determine overall survival progression-free survival patient . - Determine 20S proteasome inhibition peripheral blood mononuclear cell ( PBMC ) patient . - Determine effect bortezomib NF-kB pathway PBMC serum sample . - Identify biomarkers clinical response bortezomib docetaxel PBMC serum . - Determine quality life , symptom burden , physical function outcome patient treat regimen . OUTLINE : This prospective , open-label , nonrandomized study . Patients receive docetaxel* IV 30 minute bortezomib IV day 1 8 . Courses repeat every 28 day absence disease progression unacceptable toxicity . NOTE : *Docetaxel administer day 1 course 1 . Blood sample collect baseline , bortezomib administration day 1 course 1 , completion treatment . The pharmacodynamics pharmacogenomics bortezomib assessed peripheral blood mononuclear cell ( PBMC ) serum . After completion study treatment , patient follow every 6 week 1 year every 3 month thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx Recurrent metastatic disease Measurable disease Not candidate curative therapy PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm³ AST , ALT , alkaline phosphatase ( AP ) meet 1 follow criterion : AP normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Bilirubin normal Creatinine clearance ≤ 2.0 mg/dL No peripheral neuropathy ≥ grade 2 within past 28 day No myocardial infarction within past 6 month No New York Heart Association class III IV heart failure No uncontrolled angina No severe uncontrolled ventricular arrhythmia No electrocardiographic evidence acute ischemia active conduction system abnormalities No known hypersensitivity bortezomib , boron , mannitol No know severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No serious medical psychiatric illness would preclude study participation No malignancy within past 3 year except earlystage nonmelanomatous skin cancer , carcinoma situ cervix , earlystage prostate cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment PRIOR CONCURRENT THERAPY : No prior chemotherapy recurrent metastatic disease At least 28 day since prior concurrent investigational drug No concurrent anticancer therapy No concurrent chemotherapy No concurrent complementary herbal medicine No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
</DOC>